Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11537324 | 0.81 | KMT2A (0.48) | KMT2AMEN1ACSS2RORCUSP2 | |
| SCHEMBL11533532 | 0.80 | RAB9A (0.48) | KMT2AALDH1A1MEN1USP2RAB9A | |
| SCHEMBL20866508 | 0.79 | KMT2A (0.59) | KMT2AMEN1ACSS2 | |
| SCHEMBL11531498 | 0.76 | USP2 (0.41) | KMT2AACSS2RORCUSP2RAB9A | |
| SCHEMBL1347394 | 0.72 | KMT2A (0.54) | KMT2AALDH1A1MEN1 | |
| SCHEMBL11534182 | 0.72 | KMT2A (0.48) | KMT2AALDH1A1MEN1ACSS2RORC | |
| SCHEMBL11539389 | 0.72 | KMT2A (0.48) | KMT2AALDH1A1MEN1ACSS2 | |
| SCHEMBL4906686 | 0.71 | TLR8 (0.42) | KMT2AALDH1A1POLBMEN1RAB9A | |
| SCHEMBL4910247 | 0.71 | KMT2A (0.44) | KMT2AALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL11531880 | 0.71 | KMT2A (0.47) | KMT2AALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227811-B1 | USE OF 2-IMIDAZOLYL SUBSTITUTED CARBINOLS FOR PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASE STATES AS A RESULT OF ISCHAEMIC CONDITIONS | AVENTIS PHARMA GMBH (DE) | 2004-01-14 | — | — | EP | disclosed |
| EP-1227811-A2 | USE OF 2-IMIDAZOLYL SUBSTITUTED CARBINOLS FOR PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASE STATES AS A RESULT OF ISCHAEMIC CONDITIONS | Aventis Pharma Deutschland GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| US-6291502-B1 | Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or phophylaxis of diseases caused by ischemic conditions | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-18 | — | — | US | disclosed |
| WO-2001030327-A2 | USE OF 2-IMIDAZOLYL SUBSTITUTED CARBINOLS FOR PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF ISCHAEMIC CONDITIONS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |